nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—HTR1D—meninx—peripheral nervous system neoplasm	0.0514	0.148	CbGeAlD
Naratriptan—HTR1F—trigeminal nerve—peripheral nervous system neoplasm	0.0513	0.148	CbGeAlD
Naratriptan—HTR1B—dura mater—peripheral nervous system neoplasm	0.0489	0.141	CbGeAlD
Naratriptan—HTR1D—dura mater—peripheral nervous system neoplasm	0.0473	0.136	CbGeAlD
Naratriptan—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.021	0.0605	CbGeAlD
Naratriptan—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.0203	0.0586	CbGeAlD
Naratriptan—HTR1F—ganglion—peripheral nervous system neoplasm	0.0185	0.0533	CbGeAlD
Naratriptan—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.015	0.0431	CbGeAlD
Naratriptan—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.0145	0.0417	CbGeAlD
Naratriptan—HTR1B—ganglion—peripheral nervous system neoplasm	0.00758	0.0218	CbGeAlD
Naratriptan—HTR1D—ganglion—peripheral nervous system neoplasm	0.00734	0.0211	CbGeAlD
Naratriptan—HTR1A—ganglion—peripheral nervous system neoplasm	0.00612	0.0176	CbGeAlD
Naratriptan—MAOA—nerve—peripheral nervous system neoplasm	0.00566	0.0163	CbGeAlD
Naratriptan—MAOA—ganglion—peripheral nervous system neoplasm	0.00559	0.0161	CbGeAlD
Naratriptan—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.00372	0.0107	CbGeAlD
Naratriptan—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.0036	0.0104	CbGeAlD
Naratriptan—HTR1B—brainstem—peripheral nervous system neoplasm	0.00329	0.00949	CbGeAlD
Naratriptan—HTR1D—brainstem—peripheral nervous system neoplasm	0.00319	0.00918	CbGeAlD
Naratriptan—MAOA—trigeminal ganglion—peripheral nervous system neoplasm	0.00274	0.0079	CbGeAlD
Naratriptan—HTR1A—brainstem—peripheral nervous system neoplasm	0.00266	0.00766	CbGeAlD
Naratriptan—MAOA—parotid gland—peripheral nervous system neoplasm	0.00259	0.00745	CbGeAlD
Naratriptan—MAOA—brainstem—peripheral nervous system neoplasm	0.00243	0.00699	CbGeAlD
Naratriptan—Sumatriptan—ABCB1—peripheral nervous system neoplasm	0.00168	0.553	CrCbGaD
Naratriptan—HTR1F—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.00154	0.157	CbGpPWpGaD
Naratriptan—Eletriptan—ABCB1—peripheral nervous system neoplasm	0.00136	0.447	CrCbGaD
Naratriptan—HTR1A—cerebellum—peripheral nervous system neoplasm	0.00131	0.00377	CbGeAlD
Naratriptan—MAOA—cerebellum—peripheral nervous system neoplasm	0.0012	0.00345	CbGeAlD
Naratriptan—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.000973	0.0993	CbGpPWpGaD
Naratriptan—MAOA—Dopamine metabolism—TH—peripheral nervous system neoplasm	0.00062	0.0633	CbGpPWpGaD
Naratriptan—MAOA—Biogenic Amine Synthesis—TH—peripheral nervous system neoplasm	0.000553	0.0565	CbGpPWpGaD
Naratriptan—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000422	0.00066	CcSEcCtD
Naratriptan—Rash—Topotecan—peripheral nervous system neoplasm	0.000422	0.000659	CcSEcCtD
Naratriptan—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000421	0.000659	CcSEcCtD
Naratriptan—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.00042	0.000657	CcSEcCtD
Naratriptan—Cough—Etoposide—peripheral nervous system neoplasm	0.00042	0.000656	CcSEcCtD
Naratriptan—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.00042	0.000656	CcSEcCtD
Naratriptan—Headache—Topotecan—peripheral nervous system neoplasm	0.000419	0.000655	CcSEcCtD
Naratriptan—Rash—Tretinoin—peripheral nervous system neoplasm	0.000418	0.000654	CcSEcCtD
Naratriptan—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000418	0.000654	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000418	0.000654	CcSEcCtD
Naratriptan—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000418	0.000653	CcSEcCtD
Naratriptan—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000418	0.000653	CcSEcCtD
Naratriptan—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000418	0.000653	CcSEcCtD
Naratriptan—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000417	0.000651	CcSEcCtD
Naratriptan—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000417	0.000651	CcSEcCtD
Naratriptan—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000416	0.000651	CcSEcCtD
Naratriptan—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000416	0.000651	CcSEcCtD
Naratriptan—Headache—Tretinoin—peripheral nervous system neoplasm	0.000416	0.00065	CcSEcCtD
Naratriptan—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000416	0.00065	CcSEcCtD
Naratriptan—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000415	0.000648	CcSEcCtD
Naratriptan—Pain—Vincristine—peripheral nervous system neoplasm	0.000414	0.000648	CcSEcCtD
Naratriptan—Constipation—Vincristine—peripheral nervous system neoplasm	0.000414	0.000648	CcSEcCtD
Naratriptan—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000414	0.000647	CcSEcCtD
Naratriptan—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.000413	0.000646	CcSEcCtD
Naratriptan—Rash—Melphalan—peripheral nervous system neoplasm	0.000413	0.000646	CcSEcCtD
Naratriptan—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000413	0.000645	CcSEcCtD
Naratriptan—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.00041	0.000641	CcSEcCtD
Naratriptan—Migraine—Doxorubicin—peripheral nervous system neoplasm	0.000408	0.000637	CcSEcCtD
Naratriptan—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000405	0.000632	CcSEcCtD
Naratriptan—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.0004	0.000626	CcSEcCtD
Naratriptan—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.0004	0.000625	CcSEcCtD
Naratriptan—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.0004	0.000624	CcSEcCtD
Naratriptan—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000398	0.000621	CcSEcCtD
Naratriptan—Nausea—Topotecan—peripheral nervous system neoplasm	0.000397	0.000621	CcSEcCtD
Naratriptan—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000396	0.000619	CcSEcCtD
Naratriptan—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000396	0.000619	CcSEcCtD
Naratriptan—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000394	0.000616	CcSEcCtD
Naratriptan—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000394	0.000616	CcSEcCtD
Naratriptan—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000393	0.000614	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.00039	0.00061	CcSEcCtD
Naratriptan—Infection—Etoposide—peripheral nervous system neoplasm	0.00039	0.00061	CcSEcCtD
Naratriptan—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000389	0.000608	CcSEcCtD
Naratriptan—Nausea—Melphalan—peripheral nervous system neoplasm	0.000389	0.000608	CcSEcCtD
Naratriptan—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000387	0.000605	CcSEcCtD
Naratriptan—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000385	0.000602	CcSEcCtD
Naratriptan—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000385	0.000601	CcSEcCtD
Naratriptan—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000384	0.000601	CcSEcCtD
Naratriptan—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000383	0.000599	CcSEcCtD
Naratriptan—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000383	0.000598	CcSEcCtD
Naratriptan—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000382	0.000597	CcSEcCtD
Naratriptan—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000381	0.000596	CcSEcCtD
Naratriptan—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.00038	0.000594	CcSEcCtD
Naratriptan—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00038	0.000593	CcSEcCtD
Naratriptan—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000377	0.000589	CcSEcCtD
Naratriptan—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000372	0.000582	CcSEcCtD
Naratriptan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000371	0.00058	CcSEcCtD
Naratriptan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000371	0.000579	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00037	0.000578	CcSEcCtD
Naratriptan—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000367	0.000573	CcSEcCtD
Naratriptan—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000367	0.000573	CcSEcCtD
Naratriptan—Pain—Cisplatin—peripheral nervous system neoplasm	0.000366	0.000573	CcSEcCtD
Naratriptan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000361	0.000564	CcSEcCtD
Naratriptan—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.00056	CcSEcCtD
Naratriptan—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000358	0.000559	CcSEcCtD
Naratriptan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000357	0.000558	CcSEcCtD
Naratriptan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000356	0.000556	CcSEcCtD
Naratriptan—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000353	0.000552	CcSEcCtD
Naratriptan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000353	0.000552	CcSEcCtD
Naratriptan—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000353	0.000551	CcSEcCtD
Naratriptan—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00035	0.000547	CcSEcCtD
Naratriptan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000349	0.000546	CcSEcCtD
Naratriptan—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000349	0.000545	CcSEcCtD
Naratriptan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000349	0.000545	CcSEcCtD
Naratriptan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000348	0.000543	CcSEcCtD
Naratriptan—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000347	0.000542	CcSEcCtD
Naratriptan—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000345	0.000539	CcSEcCtD
Naratriptan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000345	0.000539	CcSEcCtD
Naratriptan—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000344	0.000538	CcSEcCtD
Naratriptan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000344	0.000538	CcSEcCtD
Naratriptan—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000342	0.000535	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000339	0.00053	CcSEcCtD
Naratriptan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000339	0.000529	CcSEcCtD
Naratriptan—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000339	0.000529	CcSEcCtD
Naratriptan—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000338	0.000529	CcSEcCtD
Naratriptan—Pain—Etoposide—peripheral nervous system neoplasm	0.000336	0.000525	CcSEcCtD
Naratriptan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000336	0.000525	CcSEcCtD
Naratriptan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000333	0.00052	CcSEcCtD
Naratriptan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000332	0.000518	CcSEcCtD
Naratriptan—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000331	0.000517	CcSEcCtD
Naratriptan—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000331	0.000517	CcSEcCtD
Naratriptan—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000327	0.000511	CcSEcCtD
Naratriptan—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000324	0.000506	CcSEcCtD
Naratriptan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000324	0.000506	CcSEcCtD
Naratriptan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000323	0.000505	CcSEcCtD
Naratriptan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000322	0.000504	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000322	0.0329	CbGpPWpGaD
Naratriptan—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000321	0.000502	CcSEcCtD
Naratriptan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000321	0.000501	CcSEcCtD
Naratriptan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00032	0.0005	CcSEcCtD
Naratriptan—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.000499	CcSEcCtD
Naratriptan—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000317	0.000496	CcSEcCtD
Naratriptan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000317	0.000495	CcSEcCtD
Naratriptan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000316	0.000493	CcSEcCtD
Naratriptan—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000315	0.000493	CcSEcCtD
Naratriptan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000315	0.000492	CcSEcCtD
Naratriptan—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000313	0.000489	CcSEcCtD
Naratriptan—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000312	0.000487	CcSEcCtD
Naratriptan—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000311	0.000487	CcSEcCtD
Naratriptan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.00031	0.000485	CcSEcCtD
Naratriptan—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.00031	0.000484	CcSEcCtD
Naratriptan—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000308	0.000482	CcSEcCtD
Naratriptan—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000308	0.000482	CcSEcCtD
Naratriptan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000307	0.000481	CcSEcCtD
Naratriptan—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000306	0.000478	CcSEcCtD
Naratriptan—Rash—Vincristine—peripheral nervous system neoplasm	0.000306	0.000478	CcSEcCtD
Naratriptan—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000305	0.000477	CcSEcCtD
Naratriptan—Headache—Vincristine—peripheral nervous system neoplasm	0.000304	0.000475	CcSEcCtD
Naratriptan—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.000468	CcSEcCtD
Naratriptan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000299	0.000467	CcSEcCtD
Naratriptan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000293	0.000458	CcSEcCtD
Naratriptan—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000292	0.000456	CcSEcCtD
Naratriptan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000289	0.000452	CcSEcCtD
Naratriptan—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000451	CcSEcCtD
Naratriptan—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.00045	CcSEcCtD
Naratriptan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000288	0.00045	CcSEcCtD
Naratriptan—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000288	0.000449	CcSEcCtD
Naratriptan—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000448	CcSEcCtD
Naratriptan—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000446	CcSEcCtD
Naratriptan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000282	0.00044	CcSEcCtD
Naratriptan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000281	0.000439	CcSEcCtD
Naratriptan—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.00028	0.000437	CcSEcCtD
Naratriptan—Chills—Epirubicin—peripheral nervous system neoplasm	0.000278	0.000434	CcSEcCtD
Naratriptan—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000278	0.000434	CcSEcCtD
Naratriptan—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000277	0.000432	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000274	0.028	CbGpPWpGaD
Naratriptan—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000274	0.000428	CcSEcCtD
Naratriptan—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000272	0.000426	CcSEcCtD
Naratriptan—Rash—Cisplatin—peripheral nervous system neoplasm	0.00027	0.000422	CcSEcCtD
Naratriptan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00027	0.000422	CcSEcCtD
Naratriptan—Erythema—Epirubicin—peripheral nervous system neoplasm	0.00027	0.000421	CcSEcCtD
Naratriptan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000269	0.00042	CcSEcCtD
Naratriptan—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.000418	CcSEcCtD
Naratriptan—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000266	0.000416	CcSEcCtD
Naratriptan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000406	CcSEcCtD
Naratriptan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00026	0.000406	CcSEcCtD
Naratriptan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000405	CcSEcCtD
Naratriptan—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000259	0.000405	CcSEcCtD
Naratriptan—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000257	0.000402	CcSEcCtD
Naratriptan—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.0004	CcSEcCtD
Naratriptan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000255	0.000398	CcSEcCtD
Naratriptan—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000397	CcSEcCtD
Naratriptan—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.000396	CcSEcCtD
Naratriptan—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000391	CcSEcCtD
Naratriptan—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00025	0.00039	CcSEcCtD
Naratriptan—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.00039	CcSEcCtD
Naratriptan—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000249	0.00039	CcSEcCtD
Naratriptan—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000248	0.000387	CcSEcCtD
Naratriptan—Rash—Etoposide—peripheral nervous system neoplasm	0.000248	0.000387	CcSEcCtD
Naratriptan—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000247	0.000387	CcSEcCtD
Naratriptan—Headache—Etoposide—peripheral nervous system neoplasm	0.000246	0.000384	CcSEcCtD
Naratriptan—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000243	0.00038	CcSEcCtD
Naratriptan—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000379	CcSEcCtD
Naratriptan—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000378	CcSEcCtD
Naratriptan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000375	CcSEcCtD
Naratriptan—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000372	CcSEcCtD
Naratriptan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000237	0.00037	CcSEcCtD
Naratriptan—Cough—Epirubicin—peripheral nervous system neoplasm	0.000235	0.000368	CcSEcCtD
Naratriptan—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000368	CcSEcCtD
Naratriptan—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000234	0.000365	CcSEcCtD
Naratriptan—Nausea—Etoposide—peripheral nervous system neoplasm	0.000233	0.000364	CcSEcCtD
Naratriptan—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.000362	CcSEcCtD
Naratriptan—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.00036	CcSEcCtD
Naratriptan—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000359	CcSEcCtD
Naratriptan—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000359	CcSEcCtD
Naratriptan—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000358	CcSEcCtD
Naratriptan—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000358	CcSEcCtD
Naratriptan—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000355	CcSEcCtD
Naratriptan—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000352	CcSEcCtD
Naratriptan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000351	CcSEcCtD
Naratriptan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.00035	CcSEcCtD
Naratriptan—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.00035	CcSEcCtD
Naratriptan—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000222	0.000347	CcSEcCtD
Naratriptan—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000221	0.000345	CcSEcCtD
Naratriptan—Oedema—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000344	CcSEcCtD
Naratriptan—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000344	CcSEcCtD
Naratriptan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.000343	CcSEcCtD
Naratriptan—Infection—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000342	CcSEcCtD
Naratriptan—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.00034	CcSEcCtD
Naratriptan—Shock—Epirubicin—peripheral nervous system neoplasm	0.000217	0.000338	CcSEcCtD
Naratriptan—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.000338	CcSEcCtD
Naratriptan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000216	0.000337	CcSEcCtD
Naratriptan—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000337	CcSEcCtD
Naratriptan—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000334	CcSEcCtD
Naratriptan—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000333	CcSEcCtD
Naratriptan—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000332	CcSEcCtD
Naratriptan—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000332	CcSEcCtD
Naratriptan—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000331	CcSEcCtD
Naratriptan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000328	CcSEcCtD
Naratriptan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.000325	CcSEcCtD
Naratriptan—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000321	CcSEcCtD
Naratriptan—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000321	CcSEcCtD
Naratriptan—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000318	CcSEcCtD
Naratriptan—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000318	CcSEcCtD
Naratriptan—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000316	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000313	CcSEcCtD
Naratriptan—Shock—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.000313	CcSEcCtD
Naratriptan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.000312	CcSEcCtD
Naratriptan—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000312	CcSEcCtD
Naratriptan—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000309	CcSEcCtD
Naratriptan—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000309	CcSEcCtD
Naratriptan—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000308	CcSEcCtD
Naratriptan—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000307	CcSEcCtD
Naratriptan—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000306	CcSEcCtD
Naratriptan—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000297	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000297	CcSEcCtD
Naratriptan—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000297	CcSEcCtD
Naratriptan—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000294	CcSEcCtD
Naratriptan—Pain—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000294	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.00029	CcSEcCtD
Naratriptan—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000286	CcSEcCtD
Naratriptan—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000284	CcSEcCtD
Naratriptan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000283	CcSEcCtD
Naratriptan—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000283	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00018	0.0184	CbGpPWpGaD
Naratriptan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000275	CcSEcCtD
Naratriptan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000274	CcSEcCtD
Naratriptan—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000273	CcSEcCtD
Naratriptan—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000272	CcSEcCtD
Naratriptan—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000272	CcSEcCtD
Naratriptan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000272	CcSEcCtD
Naratriptan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000262	CcSEcCtD
Naratriptan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000253	CcSEcCtD
Naratriptan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000253	CcSEcCtD
Naratriptan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000252	CcSEcCtD
Naratriptan—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000247	CcSEcCtD
Naratriptan—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000243	CcSEcCtD
Naratriptan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000235	CcSEcCtD
Naratriptan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000234	CcSEcCtD
Naratriptan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000228	CcSEcCtD
Naratriptan—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000227	CcSEcCtD
Naratriptan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000225	CcSEcCtD
Naratriptan—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000219	CcSEcCtD
Naratriptan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000218	CcSEcCtD
Naratriptan—Rash—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000217	CcSEcCtD
Naratriptan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000217	CcSEcCtD
Naratriptan—Headache—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000215	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000137	0.014	CbGpPWpGaD
Naratriptan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.00021	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000132	0.0134	CbGpPWpGaD
Naratriptan—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000204	CcSEcCtD
Naratriptan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000202	CcSEcCtD
Naratriptan—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000201	CcSEcCtD
Naratriptan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.0002	CcSEcCtD
Naratriptan—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000199	CcSEcCtD
Naratriptan—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000189	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000115	0.0118	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000113	0.0115	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000102	0.0104	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	9.27e-05	0.00947	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	8.9e-05	0.0091	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—NTS—peripheral nervous system neoplasm	8.77e-05	0.00896	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	8.6e-05	0.00878	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	8.59e-05	0.00878	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	8.49e-05	0.00868	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CD55—peripheral nervous system neoplasm	8.41e-05	0.00859	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	8.24e-05	0.00841	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	8.1e-05	0.00827	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	7.88e-05	0.00805	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	7.75e-05	0.00792	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	7.41e-05	0.00756	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	7.22e-05	0.00738	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—NTS—peripheral nervous system neoplasm	7.04e-05	0.00719	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	6.92e-05	0.00707	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CD55—peripheral nervous system neoplasm	6.75e-05	0.0069	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	6.55e-05	0.00669	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	6.51e-05	0.00665	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	6.38e-05	0.00651	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	6.28e-05	0.00641	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	6.17e-05	0.0063	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	5.88e-05	0.00601	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	5.88e-05	0.006	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.72e-05	0.00584	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	5.69e-05	0.00582	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—BCHE—peripheral nervous system neoplasm	5.67e-05	0.0058	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	5.58e-05	0.0057	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	5.39e-05	0.00551	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—VIP—peripheral nervous system neoplasm	5.34e-05	0.00545	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	5.18e-05	0.00529	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	5.07e-05	0.00518	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.96e-05	0.00506	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	4.93e-05	0.00503	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	4.86e-05	0.00496	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.86e-05	0.00496	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.5e-05	0.0046	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.41e-05	0.0045	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.32e-05	0.00441	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	4.25e-05	0.00434	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.23e-05	0.00432	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.16e-05	0.00425	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.99e-05	0.00407	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.94e-05	0.00403	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	3.86e-05	0.00394	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.86e-05	0.00394	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.86e-05	0.00394	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.76e-05	0.00384	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	3.7e-05	0.00378	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.68e-05	0.00376	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.48e-05	0.00356	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	3.46e-05	0.00353	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.45e-05	0.00352	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.41e-05	0.00349	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.38e-05	0.00345	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	3.36e-05	0.00343	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.34e-05	0.00341	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.22e-05	0.00329	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.16e-05	0.00323	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.15e-05	0.00322	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.15e-05	0.00322	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.08e-05	0.00315	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.05e-05	0.00311	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	2.94e-05	0.003	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	2.94e-05	0.003	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.91e-05	0.00297	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	2.8e-05	0.00286	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GNS—peripheral nervous system neoplasm	2.79e-05	0.00285	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.77e-05	0.00283	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—NME1—peripheral nervous system neoplasm	2.68e-05	0.00273	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.66e-05	0.00272	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.6e-05	0.00266	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—COX2—peripheral nervous system neoplasm	2.58e-05	0.00263	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	2.57e-05	0.00263	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.55e-05	0.0026	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.55e-05	0.0026	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.5e-05	0.00255	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.35e-05	0.0024	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.23e-05	0.00228	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.19e-05	0.00223	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.18e-05	0.00223	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.02e-05	0.00207	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.02e-05	0.00206	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.98e-05	0.00203	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.98e-05	0.00202	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.97e-05	0.00202	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.95e-05	0.00199	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.92e-05	0.00196	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.91e-05	0.00195	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.9e-05	0.00194	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.87e-05	0.00191	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.86e-05	0.0019	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.82e-05	0.00186	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.78e-05	0.00182	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.77e-05	0.00181	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	1.74e-05	0.00177	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.73e-05	0.00177	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ENO2—peripheral nervous system neoplasm	1.69e-05	0.00173	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.66e-05	0.0017	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.63e-05	0.00167	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.51e-05	0.00154	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.5e-05	0.00154	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.45e-05	0.00148	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—BCHE—peripheral nervous system neoplasm	1.43e-05	0.00146	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.4e-05	0.00143	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.39e-05	0.00142	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.37e-05	0.0014	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.36e-05	0.00139	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—TH—peripheral nervous system neoplasm	1.34e-05	0.00137	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—HRAS—peripheral nervous system neoplasm	1.33e-05	0.00136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.32e-05	0.00135	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.23e-05	0.00126	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.2e-05	0.00123	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.2e-05	0.00122	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.17e-05	0.0012	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.16e-05	0.00118	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.14e-05	0.00116	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.14e-05	0.00116	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.12e-05	0.00114	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GNAS—peripheral nervous system neoplasm	1.1e-05	0.00112	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ABCB1—peripheral nervous system neoplasm	1.08e-05	0.0011	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.05e-05	0.00107	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.04e-05	0.00106	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.02e-05	0.00105	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	9.17e-06	0.000937	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.98e-06	0.000917	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.92e-06	0.000911	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.5e-06	0.000868	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	8.46e-06	0.000864	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	8.22e-06	0.00084	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.15e-06	0.000832	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.8e-06	0.000796	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.47e-06	0.000763	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.39e-06	0.000755	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.26e-06	0.000742	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.24e-06	0.000739	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.11e-06	0.000726	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.83e-06	0.000698	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.36e-06	0.00065	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.74e-06	0.000586	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.62e-06	0.000574	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.51e-06	0.000563	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.42e-06	0.000553	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.41e-06	0.000552	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.3e-06	0.000541	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.26e-06	0.000537	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.22e-06	0.000534	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.21e-06	0.000532	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.15e-06	0.000526	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.1e-06	0.000521	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5e-06	0.00051	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.78e-06	0.000488	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.68e-06	0.000478	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.41e-06	0.000451	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.37e-06	0.000446	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.28e-06	0.000437	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.28e-06	0.000437	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.07e-06	0.000416	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.03e-06	0.000412	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.98e-06	0.000407	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.92e-06	0.000401	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.89e-06	0.000397	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.56e-06	0.000364	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.34e-06	0.000341	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.27e-06	0.000334	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.26e-06	0.000333	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.2e-06	0.000326	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.13e-06	0.00032	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.03e-06	0.00031	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AKT1—peripheral nervous system neoplasm	2.96e-06	0.000302	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.82e-06	0.000288	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.76e-06	0.000282	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.49e-06	0.000255	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.38e-06	0.000243	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.1e-06	0.000215	CbGpPWpGaD
